GCNT2/I-BRANCHING AS A BIOMARKER OF MELANOMA PROGRESSION
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
May 6, 2021
app pub date -
Jun 4, 2020
filing date -
Nov 6, 2019
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention provides methods and composition for diagnosis, prognosis, prevention and/or treatment of cancers such as melanomas. The subject invention provides biomarkers and methods for assessing the severity of a cancer/tumor and for monitoring the progressing of a cancer/tumor. The biomarkers include glycosylation-rerated genes and molecules affected by the glycosylation-rerated genes. The compositions according to the subject invention regulate malignancy-associated pathways and alter melanoma signaling, growth, and survival.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully